VINEETLAB Stock Overview
Engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API) and fine chemicals in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Vineet Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹58.81 |
| 52 Week High | ₹88.90 |
| 52 Week Low | ₹46.60 |
| Beta | -0.25 |
| 1 Month Change | 16.23% |
| 3 Month Change | 0.51% |
| 1 Year Change | -16.11% |
| 3 Year Change | -20.26% |
| 5 Year Change | n/a |
| Change since IPO | 27.29% |
Recent News & Updates
Recent updates
Vineet Laboratories (NSE:VINEETLAB) Seems To Be Using A Lot Of Debt
Jul 12
Earnings Working Against Vineet Laboratories Limited's (NSE:VINEETLAB) Share Price Following 25% Dive
Mar 07We Think Vineet Laboratories (NSE:VINEETLAB) Is Taking Some Risk With Its Debt
Feb 15With EPS Growth And More, Vineet Laboratories (NSE:VINEETLAB) Makes An Interesting Case
Nov 14Shareholder Returns
| VINEETLAB | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -1.8% | 0.6% | -4.2% |
| 1Y | -16.1% | 40.2% | 19.4% |
Return vs Industry: VINEETLAB underperformed the Indian Pharmaceuticals industry which returned 40.2% over the past year.
Return vs Market: VINEETLAB underperformed the Indian Market which returned 19.4% over the past year.
Price Volatility
| VINEETLAB volatility | |
|---|---|
| VINEETLAB Average Weekly Movement | 6.1% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: VINEETLAB has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: VINEETLAB's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 79 | n/a | vineetlabs.co.in |
Vineet Laboratories Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API) and fine chemicals in India. The company offers intermediates of Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine, and other API intermediates. It also provides fine chemicals and reagents, such as isopropyl-beta-d-thiogalactopyranoside, n-butyl lithium, 4-nitrophenyl phosphate disodium salt, 5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside, 5-acetyl thiophene-2-carboxilic acid, 4-chlorobutyryl chloride, n-butyl magnesium chloride, 3-furaldehyde, 3-bromofuran, n-butylnitrite, ethyldiazo acetate, phenylboronic acid, 6-aminouracil, and 1-methyl-imidazole-2-carboxaldehyde.
Vineet Laboratories Limited Fundamentals Summary
| VINEETLAB fundamental statistics | |
|---|---|
| Market cap | ₹519.31m |
| Earnings (TTM) | -₹41.01m |
| Revenue (TTM) | ₹1.13b |
0.5x
P/S Ratio-13.2x
P/E RatioIs VINEETLAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VINEETLAB income statement (TTM) | |
|---|---|
| Revenue | ₹1.13b |
| Cost of Revenue | ₹892.35m |
| Gross Profit | ₹241.85m |
| Other Expenses | ₹282.86m |
| Earnings | -₹41.01m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.45 |
| Gross Margin | 21.32% |
| Net Profit Margin | -3.62% |
| Debt/Equity Ratio | 131.9% |
How did VINEETLAB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 15:10 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Vineet Laboratories Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|